Mount Sinai Morningside is a clinical research site located in New York, New York, United States 10025.
Crixeo Health Trust Score: 81/100 (GOOD). This profile has not yet been claimed by the site owner.
Mount Sinai Morningside has participated in 17 clinical trials with 14 currently active.
Therapeutic areas: COVID-19, Aortic Stenosis, Mitral Stenosis.
Sponsors: Kinevant Sciences GmbH, Edwards Lifesciences, Novo Nordisk A/S.
Trust Score: 81/100. Verification status: Crixeo Accredited. Patient reviews: 0. Complaints: 0.
Mount Sinai Morningside has a Crixeo Trust Score of 81/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Mount Sinai Morningside has 17 clinical trials on record, with 14 currently active. Their work covers COVID-19, Aortic Stenosis, Mitral Stenosis.
Yes — Mount Sinai Morningside holds Crixeo Accreditation, the quality standard for clinical research sites. Accredited sites have verified compliance documents, strong patient reviews, and sponsor transparency.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.